Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 4/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL440397 | 1.00 | LMNA (0.64) | LMNASMN1; SMN2RAB9ACA2POLB | |
| SCHEMBL5845241 | 1.00 | LMNA (0.64) | LMNASMN1; SMN2RAB9ACA2POLB | |
| SCHEMBL6973472 | 0.88 | CA2 (0.57) | LMNASMN1; SMN2RAB9ACA2ALDH1A1 | |
| SCHEMBL10832816 | 0.88 | CA2 (0.51) | LMNASMN1; SMN2RAB9ACA2ALDH1A1 | |
| SCHEMBL6973466 | 0.88 | CA2 (0.57) | LMNASMN1; SMN2RAB9ACA2ALDH1A1 | |
| SCHEMBL7966432 | 0.87 | LMNA (0.61) | LMNASMN1; SMN2RAB9ACA2POLB | |
| SCHEMBL11102654 | 0.87 | LMNA (0.48) | LMNASMN1; SMN2RAB9ACA2ALDH1A1 | |
| SCHEMBL6976444 | 0.86 | LMNA (0.48) | LMNASMN1; SMN2RAB9ACA2POLB | |
| SCHEMBL6976439 | 0.86 | LMNA (0.48) | LMNASMN1; SMN2RAB9ACA2POLB | |
| SCHEMBL7782073 | 0.86 | LMNA (0.48) | LMNASMN1; SMN2RAB9ACA2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3233077-B1 | DOPAMINE D2 RECEPTOR LIGANDS | BROAD INST INC (US) | 2026-05-06 | — | — | EP | disclosed |
| US-12428373-B2 | Dopamine D2 receptor ligands | THE BROAD INSTITUTE, INC. (US) | 2025-09-30 | — | — | US | disclosed |
| US-20230143552-A1 | DOPAMINE D2 RECEPTOR LIGANDS | THE BROAD INSTITUTE, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230143552-A1 | DOPAMINE D2 RECEPTOR LIGANDS | THE BROAD INSTITUTE, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-11498896-B2 | Dopamine D2 receptor ligands | THE BROAD INSTITUTE, INC. (US) | 2022-11-15 | — | — | US | disclosed |
| US-20210147355-A1 | DOPAMINE D2 RECEPTOR LIGANDS | THE BROAD INSTITUTE, INC. (US) | 2021-05-20 | — | — | US | disclosed |
| US-10633336-B2 | Dopamine D2 receptor ligands | THE BROAD INSTITUTE, INC. (US) | 2020-04-28 | — | — | US | disclosed |
| US-20190152992-A1 | BENZODIOXANE DERIVATIVES AND THEIR PHARMACEUTICAL USE | ORION CORPORATION (FI) | 2019-05-23 | — | — | US | disclosed |
| US-20180155283-A1 | DOPAMINE D2 RECEPTOR LIGANDS | THE BROAD INSTITUTE, INC. (US) | 2018-06-07 | — | — | US | disclosed |
| US-20180155283-A1 | DOPAMINE D2 RECEPTOR LIGANDS | THE BROAD INSTITUTE, INC. (US) | 2018-06-07 | — | — | US | disclosed |
| US-5234948-A | Treating anxiety | MITSUBISHI KASEI CORPORATION (JP) | 1993-08-10 | — | — | US | disclosed |
| US-5168099-A | Anxiolytic agents | MITSUBISHI KASEI CORPORATION (JP) | 1992-12-01 | — | — | US | disclosed |
| EP-0422134-A4 | 5-HT SELECTIVE AGENTS | — | 1992-05-06 | — | — | EP | disclosed |
| EP-0446921-A2 | Optically active alkylene-dioxybenzene derivatives and their use in therapy | Mitsubishi Chemical Corporation (JP) | 1991-09-18 | — | — | EP | disclosed |
| US-5049564-A | Hypotensive, 5-hydroxytryptamine | ABBOTT LABORATORIES (US) | 1991-09-17 | — | — | US | disclosed |
| EP-0422134-A1 | 5-HT SELECTIVE AGENTS. | ABBOTT LAB (US) | 1991-04-17 | — | — | EP | disclosed |
| WO-1990006927-A1 | 5-HT SELECTIVE AGENTS | ABBOTT LABORATORIES (US) | 1990-06-28 | — | — | WO | disclosed |
| EP-0095666-B1 | TETRAHYDRO-BENZO(E) ISOINDOLINES | ABBOTT LABORATORIES (US) | 1989-01-18 | — | — | EP | disclosed |
| EP-0199400-A2 | Substituted N-[(4-piperidinyl)alkyl] bicyclic condensed ozazol- and thiazolamines | JANSSEN PHARMACEUTICA N.V. (BE) | 1986-10-29 | — | — | EP | disclosed |
| EP-0095666-A2 | Tetrahydro-benzo(e) isoindolines | ABBOTT LABORATORIES (US) | 1983-12-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180155283-A1 | DOPAMINE D2 RECEPTOR LIGANDS | DRD2, DRD3, ARRB1 | LMNA 4642/4885SMN1; SMN2 2087/4885RAB9A 889/4885 |
| US-11498896-B2 | Dopamine D2 receptor ligands | DRD2, SLC6A3, NTSR2 | LMNA 4865/4885SMN1; SMN2 1443/4885RAB9A 906/4885 |
| US-10633336-B2 | Dopamine D2 receptor ligands | DRD2, ARRB1, DRD3 | LMNA 4825/4885SMN1; SMN2 2679/4885RAB9A 920/4885 |
| US-20230143552-A1 | DOPAMINE D2 RECEPTOR LIGANDS | DRD2, SLC6A3, NTSR2 | LMNA 4865/4885SMN1; SMN2 1443/4885RAB9A 906/4885 |
| US-20210147355-A1 | DOPAMINE D2 RECEPTOR LIGANDS | DRD2, SLC6A3, NTSR2 | LMNA 4865/4885SMN1; SMN2 1443/4885RAB9A 906/4885 |
| US-12428373-B2 | Dopamine D2 receptor ligands | DRD2, SLC6A3, NTSR2 | LMNA 4865/4885SMN1; SMN2 1443/4885RAB9A 906/4885 |
| US-20190152992-A1 | BENZODIOXANE DERIVATIVES AND THEIR PHARMACEUTICAL USE | TBXA2R, ADRA2C, ADRB2 | LMNA 2674/4885SMN1; SMN2 1954/4885RAB9A 2884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.